Author:
Hsieh E.,Fraenkel L.,Xia W.,Hu Y. Y.,Han Y.,Insogna K.,Yin M. T.,Xie J.,Zhu T.,Li T.
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology, Diabetes and Metabolism
Reference42 articles.
1. Mondy K, Yarasheski K, Powderly WG et al (2003) Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 36(4):482–901
2. Piso RJ, Rothen M, Rothen JP, Stahl M (2011) Markers of bone turnover are elevated in patients with antiretroviral treatment independent of the substance used. J Acquir Immune Defic Syndr 56(4):320–324
3. Yin MT, McMahon DJ, Ferris DC et al (2010) Low bone mass and high bone turnover in postmenopausal human immunodeficiency virus-infected women. J Clin Endocrinol Metab 95:620–629
4. Van Vonderen M.G., Mallon P, Murray B, et al. Changes in bone biomarkers in antiretroviral naïve HIV-infected men randomized to nevirapine/lopinavir/ritonavir or zidovudine/lamivudine /lopinavir/ritonavir help explain limited loss of bone mineral density over first 12 months after antiretroviral therapy initiation. 18th Conference on Retroviruses and Opportunistic Infections. Feb 27-Mar 2, 2011. Boston, MA.
5. Squires KE, Gulick R, Tebas P et al (2000) A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I). AIDS 14(11):1591–1600
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献